May 16, 2017 7:05am EDT Immunovaccine's Lead Immuno-Oncology Candidate to Enter Investigator-Sponsored Phase 2 Clinical Trial in DLBCL in Combination with Approved Anti-PD-1 Drug
May 02, 2017 7:05am EDT Immunovaccine to Present at 19th Annual TIDES: Oligonucleotide and Peptide Therapeutics Conference
Apr 18, 2017 7:05am EDT Immunovaccine Announces Dosing of First Patient in Investigator-Sponsored Phase 1b/2 Clinical Trial Evaluating Immuno-Oncology Candidate Targeting Incurable HPV-Related Cancers
Apr 12, 2017 7:05am EDT Immunovaccine Announces Positive Year-Long Immunogenicity Data from Phase 1 Clinical Trial for Respiratory Syncytial Virus Vaccine Candidate
Apr 11, 2017 7:05am EDT Princess Margaret Cancer Center Receives Health Canada Clearance to Begin Investigator-Sponsored Phase 2 Ovarian Cancer Study Evaluating Immunovaccine's DPX-Survivac with Merck's Pembrolizumab
Apr 07, 2017 7:05am EDT Immunovaccine to Present at Bloom Burton & Co. Healthcare Investor Conference
Apr 05, 2017 7:05am EDT Immunovaccine Inc. Presents Preclinical Research at AACR 2017 on Ability of Novel Monoclonal Antibodies to Boost Efficacy of DepoVax(TM)-based Cancer Immunotherapy
Mar 29, 2017 7:05am EDT Immunovaccine Announces Positive Interim Clinical Data from Ovarian Cancer Study of DPX-Survivac in Combination with Epacadostat